Gilead Sciences, Inc. Peer Comparison
Metric | Value | Ranking | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $128.8 Billion | 8/9 | LLY $828.7B |
JNJ $373.8B |
ABBV $341.1B |
AZN $230.8B |
MRK $216.7B |
AMGN $158.6B |
PFE $144.3B |
GILD $128.8B |
BMY $113.9B |
Gross Margin | -100% | 9/9 | LLY 82% |
MRK 80% |
AZN 77% |
BMY 75% |
ABBV 71% |
PFE 70% |
JNJ 70% |
AMGN 61% |
GILD -100% |
Profit Margin | 17% | 5/9 | AMGN 33% |
LLY 33% |
PFE 25% |
MRK 19% |
GILD 17% |
JNJ 12% |
ABBV 11% |
AZN 11% |
BMY 10% |
EBITDA margin | 12% | 9/9 | ABBV 49% |
LLY 45% |
BMY 38% |
JNJ 32% |
PFE 31% |
AZN 30% |
MRK 25% |
AMGN 24% |
GILD 12% |
Quarterly Revenue | $7.6 Billion | 9/9 | JNJ $22.5B |
PFE $17.7B |
MRK $16.7B |
ABBV $14.5B |
AZN $13.6B |
LLY $13.5B |
BMY $11.9B |
AMGN $8.5B |
GILD $7.6B |
Quarterly Earnings | $1.3 Billion | 8/9 | PFE $4.5B |
LLY $4.4B |
MRK $3.2B |
AMGN $2.8B |
JNJ $2.7B |
ABBV $1.6B |
AZN $1.4B |
GILD $1.3B |
BMY $1.2B |
Quarterly Free Cash Flow | $4.5 Billion | 5/9 | MRK $8.5B |
PFE $6.1B |
BMY $5.3B |
ABBV $5.2B |
GILD $4.5B |
AMGN $3.3B |
AZN $2.0B |
JNJ -$0 |
LLY -$0 |
Trailing 4 Quarters Revenue | $28.3 Billion | 9/9 | JNJ $87.7B |
MRK $63.2B |
PFE $60.1B |
ABBV $55.5B |
AZN $51.2B |
BMY $47.4B |
LLY $45.0B |
AMGN $32.5B |
GILD $28.3B |
Trailing 4 Quarters Earnings | $126.0 Million | 8/9 | JNJ $22.5B |
PFE $17.7B |
MRK $16.7B |
ABBV $14.5B |
AZN $13.6B |
LLY $13.5B |
BMY $11.9B |
AMGN $8.5B |
GILD $7.6B |
Quarterly Earnings Growth | -43% | 8/9 | PFE 287% |
LLY 101% |
AMGN 64% |
AZN 4% |
ABBV -12% |
MRK -33% |
BMY -37% |
GILD -43% |
JNJ -90% |
Annual Earnings Growth | -98% | 8/9 | LLY 425% |
MRK 192% |
AZN -5% |
PFE -8% |
AMGN -28% |
ABBV -35% |
JNJ -65% |
GILD -98% |
BMY -189% |
Quarterly Revenue Growth | 7% | 6/9 | LLY 45% |
PFE 34% |
AMGN 23% |
AZN 18% |
BMY 8% |
GILD 7% |
JNJ 5% |
ABBV 4% |
MRK 4% |
Annual Revenue Growth | 5% | 6/9 | LLY 19% |
PFE 17% |
AMGN 17% |
AZN 12% |
BMY 6% |
GILD 5% |
MRK 3% |
ABBV 0% |
JNJ -10% |
Cash On Hand | $0 | 7/9 | MRK $14.6B |
AMGN $9.0B |
BMY $7.9B |
ABBV $7.3B |
AZN $4.8B |
PFE $1.1B |
GILD -$0 |
JNJ -$0 |
LLY -$0 |
Short Term Debt | $0 | 7/9 | ABBV $12.6B |
AMGN $3.5B |
MRK $3.1B |
PFE $2.9B |
AZN $1.6B |
BMY $1.1B |
GILD -$0 |
JNJ -$0 |
LLY -$0 |
Long Term Debt | $0 | 7/9 | ABBV $58.5B |
PFE $58.0B |
AMGN $56.9B |
BMY $48.7B |
MRK $35.0B |
AZN $30.0B |
GILD $0 |
JNJ $0 |
LLY $0 |
PE | 1021.84 | 1/9 | GILD 1021.84 |
LLY 78.26 |
ABBV 66.51 |
AMGN 37.50 |
AZN 35.54 |
PFE 34.08 |
JNJ 25.46 |
MRK 17.84 |
BMY -1.00 |
PS | 4.55 | 4/9 | LLY 18.40 |
ABBV 6.14 |
AMGN 4.88 |
GILD 4.55 |
AZN 4.51 |
JNJ 4.26 |
MRK 3.43 |
PFE 2.40 |
BMY 2.40 |
PB | 3.01 | 8/9 | LLY 57.87 |
ABBV 56.18 |
AMGN 21.07 |
BMY 6.62 |
AZN 5.66 |
JNJ 5.23 |
MRK 4.86 |
GILD 3.01 |
PFE 1.81 |
PC | -1.00 | 7/9 | PFE 132.18 |
AZN 48.12 |
ABBV 47.00 |
AMGN 17.60 |
MRK 14.85 |
BMY 14.43 |
GILD -1.00 |
JNJ -1.00 |
LLY -1.00 |
Liabilities to Equity | 0.00 | 7/9 | ABBV 22.77 |
AMGN 11.07 |
BMY 4.46 |
MRK 1.64 |
AZN 1.57 |
PFE 1.38 |
GILD 0.00 |
JNJ -1.00 |
LLY -1.00 |
ROA | 0.00 | 6/9 | MRK 10% | AZN 6% | AMGN 5% | ABBV 4% | PFE 2% | GILD 0% | BMY -8% | JNJ -100% | LLY -100% |
ROE | -1.00 | 9/9 | ABBV 85% |
LLY 74% |
AMGN 56% |
MRK 27% |
JNJ 21% |
AZN 16% |
PFE 5% |
BMY -42% |
GILD -100% |
Current Ratio | 4.65 | 1/9 | GILD 4.65 |
AZN 1.64 |
PFE 1.63 |
MRK 1.61 |
BMY 1.22 |
AMGN 1.09 |
ABBV 1.04 |
JNJ 0.00 |
LLY 0.00 |
Quick Ratio | 0.43 | 1/9 | GILD 1021.84 |
LLY 78.26 |
ABBV 66.51 |
AMGN 37.50 |
AZN 35.54 |
PFE 34.08 |
JNJ 25.46 |
MRK 17.84 |
BMY -1.00 |
Long Term Debt to Equity | -1.00 | 9/9 | ABBV} 9.70 |
AMGN} 7.55 |
BMY} 2.84 |
MRK} 0.79 |
AZN} 0.74 |
PFE} 0.63 |
JNJ} 0.00 |
LLY} 0.00 |
GILD} -1.00 |
Debt to Equity | -1.00 | 9/9 | ABBV 11.78 |
AMGN 8.02 |
BMY 2.90 |
MRK 0.86 |
AZN 0.78 |
PFE 0.63 |
JNJ 0.00 |
LLY 0.00 |
GILD -1.00 |
Burn Rate | 0.00 | 5/9 | AZN 29.40 |
AMGN 27.29 |
BMY 7.85 |
ABBV 1.85 |
GILD 0.00 |
JNJ 0.00 |
LLY 0.00 |
PFE -0.77 |
MRK -15.04 |
Cash to Cap | 0.00 | 7/9 | BMY 0.07 |
MRK 0.07 |
AMGN 0.06 |
ABBV 0.02 |
AZN 0.02 |
PFE 0.01 |
GILD 0.00 |
JNJ 0.00 |
LLY 0.00 |
CCR | 3.63 | 2/9 | BMY 4.35 |
GILD 3.63 |
ABBV 3.33 |
MRK 2.69 |
AZN 1.42 |
PFE 1.36 |
AMGN 1.17 |
JNJ 0.00 |
LLY 0.00 |
EV to EBITDA | 144.99 | 1/9 | GILD} 144.99 |
LLY} 134.78 |
AMGN} 102.58 |
AZN} 62.79 |
MRK} 58.74 |
ABBV} 57.49 |
JNJ} 52.65 |
PFE} 36.58 |
BMY} 34.02 |
EV to Revenue | 4.55 | 5/9 | LLY 18.40 |
ABBV 7.29 |
AMGN 6.46 |
AZN 5.03 |
GILD 4.55 |
JNJ 4.26 |
MRK 3.80 |
PFE 3.35 |
BMY 3.28 |